It is noteworthy that both protein and mRNA levels of PARP16 were distinctly upregulated in PE-treated H9C2 cells and NRCMs (Fig. 2e, f and Fig. S2b), implying that PARP16 may be correlated with the progress of pathological cardiac hypertrophy. This evidence concerns the gene PARP16 and cardiac hypertrophy.